Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Research and Innovation Action · Running

TBVAC-HORIZON Improving understanding of lung immunity in tuberculosis to establish a diverse, innovative TB vaccine pipeline targeting mucosal immunity

Coordinator
Stichting Tuberculosis Vaccine Initiative, Netherlands
Runs
1 April 2023 to 31 March 2027
Status
Running
EU funding
€6.2m
Total cost
€7.1m
Partners
19 organisations in 8 countries
Type
Research and Innovation Action
Grant agreement
101080309

What the project is doing

In the project's own words, from its summary on CORDIS.

Tuberculosis (TB) remains one of the most devastating infectious diseases worldwide, killing over 4,000 people every day. Prevention of tuberculosis infection by novel vaccines would provide the most cost-effective approach to achieve the goals of the WHO End TB strategy and the Sustainable Development Goals of the United Nations. While there are few promising TB vaccine candidates available, innovation by new platforms and strategies is needed to ensure that the most effective and affordable vaccines are developed.

TBVACHORIZON will innovate and diversify the global TB vaccine pipeline by pursuing four objectives:1.Define the composition, spatial organisation and functioning of protective immune responses in the Mycobacterium tuberculosis-infected lung.2.Evaluate whether mucosal re-vaccination with BCG and other live attenuated vaccines improves protective efficacy against tuberculosis infection in mice, non-human primates and humans.3.Identify host immune response profiles and biomarkers of natural and vaccine-induced immune protection in the lung.4.Support next generation TB vaccine development by standardised head-to-head testing of selected vaccine candidates in animals and the establishment of novel delivery systems, adjuvant formulations and GMP platforms for live attenuated vaccines.

TBVACHORIZON will increase our understanding and develop tools pertaining to immune protection in the lung, the major site of tuberculosis infection. This knowledge will be exploited to develop mucosal strategies for translating towards clinical evaluation and possible implementation. The interwoven activities will consolidate Europe’s leading role in TB vaccine research and innovation, with the ultimate goal of accelerated availability of affordable, accessible and more effective TB vaccines.

Topics

Who is involved

OrganisationCityCountryRole
Stichting Tuberculosis Vaccine InitiativeLelystadNetherlandsCoordinator
Universitat BaselBaselSwitzerlandAssociatedpartner
Vaccine Formulation Institute(ch)ltdPlan Les OuatesSwitzerlandAssociatedpartner
Universitaet UlmUlmGermanyParticipant
Statens Serum InstitutKobenhavn SDenmarkParticipant
Cz Vaccines SAPorrinoSpainParticipant
Universidad De ZaragozaZaragozaSpainParticipant
Centre National De La Recherche Scientifique CNRSParisFranceParticipant
Institut PasteurParisFranceParticipant
Institut Pasteur De Lille FondationLilleFranceParticipant
Universite De ToulouseToulouseFranceThird party
Istituto Nazionale per Le Malattie Infettive Lazzaro Spallanzani-Istituto Di Ricovero E Cura a Carattere ScientificoRomaItalyParticipant
Academisch Ziekenhuis LeidenLeidenNetherlandsParticipant
Stichting Biomedical Primate Research CenterRijswijk ZhNetherlandsParticipant
Department of HealthLeedsUnited KingdomAssociatedpartner
London School of Hygiene and Tropical Medicine Royal CharterLondonUnited KingdomAssociatedpartner
Medicines and Healthcare Products Regulatory AgencyLondonUnited KingdomAssociatedpartner
The Chancellor, Masters and Scholars of the University of OxfordOxfordUnited KingdomAssociatedpartner
University of LeicesterLeicesterUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI